Aurobindo Pharma Limited (NSE:AUROPHARMA)
1,568.80
-18.60 (-1.17%)
Jul 10, 2026, 3:30 PM IST
Aurobindo Pharma Revenue
In the fiscal year ending March 31, 2026, Aurobindo Pharma had annual revenue of 336.53B INR with 6.08% growth. Aurobindo Pharma had revenue of 88.53B in the quarter ending March 31, 2026, with 5.62% growth.
Revenue
336.53B
Revenue Growth
+6.08%
P/S Ratio
2.68
Revenue / Employee
12.15M
Employees
27,707
Market Cap
900.29B
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 336.53B | 19.29B | 6.08% |
| Mar 31, 2025 | 317.24B | 27.22B | 9.39% |
| Mar 31, 2024 | 290.02B | 41.46B | 16.68% |
| Mar 31, 2023 | 248.55B | 14.00B | 5.97% |
| Mar 31, 2022 | 234.55B | -13.19B | -5.32% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Cipla | 278.28B |
| Zydus Lifesciences | 271.48B |
| Glenmark Pharmaceuticals | 169.83B |
| Alkem Laboratories | 147.12B |
| Mankind Pharma | 142.78B |
| Divi's Laboratories | 105.60B |
| Ipca Laboratories | 96.46B |
| Emcure Pharmaceuticals | 92.04B |
Aurobindo Pharma News
- 9 days ago - Pharma sector stocks surge today, July 3: Aurobindo Pharma jumps 2.74%, Sudeep Pharma gains 2.43%, Lupin up 1.95% - Business Upturn
- 10 days ago - Aurobindo Pharma completes transfer of domestic branded generics to subsidiary - Business Upturn
- 12 days ago - Pharma sector stocks today, June 30: Ajanta Pharma falls 2.96%, Dr. Reddy's Lab down 1.77%, Aurobindo Pharma up 1.41% - Business Upturn
- 12 days ago - Aurobindo Pharma completes acquisition of Lannett Company - Business Upturn
- 15 days ago - Aurobindo Pharma's subsidiary faces two US FDA observations after inspection - Business Upturn
- 17 days ago - Aurobindo Pharma completes solar power agreement with Rs 52 lakh investment - Business Upturn
- 20 days ago - Aurobindo gets US FTC nod to acquire Lannett Co for $250 million - The Times of India
- 20 days ago - HSBC maintains Buy on Aurobindo Pharma, sees progress toward $2 billion US sales goal - Business Upturn